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&Magnetic Resonance Imaging
Dual-Modal Magnetic Resonance/Fluorescent Zinc Probes for
Pancreatic b-Cell Mass Imaging
Graeme J. Stasiuk,[a] Florencia Minuzzi,[b] Myra Sae-Heng,[a] Charlotte Rivas,[a]
Hans-Paul Juretschke,[c] Lorenzo Piemonti,[d] Peter R. Allegrini,[e] Didier Laurent,[f]
Andrew R. Duckworth,[g] Andrew Beeby,[g] Guy A. Rutter,*[b] and Nicholas J. Long*[a]
Abstract: Despite the contribution of changes in pancreatic
b-cell mass to the development of all forms of diabetes mel-
litus, few robust approaches currently exist to monitor these
changes prospectively in vivo. Although magnetic-resonance
imaging (MRI) provides a potentially useful technique, tar-
geting MRI-active probes to the b cell has proved challeng-
ing. Zinc ions are highly concentrated in the secretory gran-
ule, but they are relatively less abundant in the exocrine
pancreas and in other tissues. We have therefore developed
functional dual-modal probes based on transition-metal che-
lates capable of binding zinc. The first of these, Gd·1, binds
ZnII directly by means of an amidoquinoline moiety (AQA),
thus causing a large ratiometric Stokes shift in the fluores-
cence from lem=410 to 500 nm with an increase in relaxivity
from r1=4.2 up to 4.9 mm
1 s1. The probe is efficiently accu-
mulated into secretory granules in b-cell-derived lines and
isolated islets, but more poorly by non-endocrine cells, and
leads to a reduction in T1 in human islets. In vivo murine
studies of Gd·1 have shown accumulation of the probe in
the pancreas with increased signal intensity over 140 mi-
nutes.
Introduction
Changes in pancreatic b-cell mass contribute to the develop-
ment of both type 1 and type 2 diabetes (T1D and T2D, re-
spectively), diseases that currently affect more than 340 million
individuals worldwide[1] and whose incidence in adults is pro-
jected to increase by approximately 20% by 2030. Whereas
immune cell-mediated mechanisms lead to near-complete
elimination of b cells in T1D, both the extent of the loss (esti-
mates range from approximately 35[2] to 60%)[3] and the under-
lying mechanisms are less well established for T2D.[4] Nonethe-
less, these are likely to involve the interplay of genetic and en-
vironmental factors, including obesity. A critical roadblock in
understanding both disease mechanisms and progression is,
however, the absence of robust approaches to following
changes in b-cell mass prospectively in vivo.
Compared with other modalities, magnetic resonance (MR)
imaging has excellent anatomical resolution but suffers on the
molecular scale from low intrinsic sensitivity. Thus, to produce
a detectable change in water signal intensity, a relatively high
concentration of contrast agent (0.01–0.1 mmolkg1) is re-
quired. This creates problems when imaging at the molecular
level, as the most interesting (i.e. , cell-type-specific) targets are
likely to be present at much lower concentrations (pm–nm).
Dual-modal imaging potentially offers important advantages.
Here, the goal is to overlay images obtained by different tech-
niques, thereby giving better image resolution and co-valida-
tion of the accumulation of targeted contrast agents (for ex-
ample, in animal models) or probes at a specific site.[5]
[a] Dr. G. J. Stasiuk, Dr. M. Sae-Heng, C. Rivas, Prof. N. J. Long
Department of Chemistry, Imperial College London
South Kensington Campus, London SW7 2AZ (UK)
E-mail : n.long@imperial.ac.uk
[b] Dr. F. Minuzzi, Prof. G. A. Rutter
Section of Cell Biology and Functional Genomics
Division of Diabetes, Endocrinology and Metabolism
Department of Medicine, Imperial College London
Hammersmith Hospital, London W12 0NN (UK)
E-mail : g.rutter@imperial.ac.uk
[c] Dr. H.-P. Juretschke
Sanofi-Aventis Deutschland GmbH
R&D DSAR/Biomakers, Biom & Biol Ass, FF
Industriepark Hoechst, Building H825
65926 Frankfurt (Germany)
[d] Dr. L. Piemonti
Diabetes Research Institute, IRCCS San Raffaele Scientific Institute
Via Olgettina 60, 20132 Milano (Italy)
[e] Dr. P. R. Allegrini
Novartis Pharma AG
Fabrikstrasse, 28-3.04, 4002 Basel (Switzerland)
[f] Dr. D. Laurent
Novartis Institute for Biomedical Research
Fabrikstrasse, 10-2.40.4, 4056, Basel (Switzerland)
[g] A. R. Duckworth, Prof. A. Beeby
Department of Chemistry, Durham University
South Road, Durham, DH1 3LE (UK)
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/chem.201406008.
 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
This is an open access article under the terms of the Creative Commons At-
tribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
Chem. Eur. J. 2015, 21, 5023 – 5033  2015 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim5023
Full PaperDOI: 10.1002/chem.201406008
Over the last fifteen years, research into contrast agents that
respond to different concentrations of metal ions, such as CaII,
FeII/III and ZnII, has given an indication of disease states and
become a key area of interest.[6] These probes can be split into
three classes: fluorescent, MRI, and more recently, dual-modal
imaging agents. There has been considerable interest in zinc
sensing for disease states such as diabetes. For example, a
plethora of ZnII-sensing fluorescent probes based on a variety
of organic fluorophores such as 4,4-difluoro-4-bora-3a,4a-
diaza-s-indacene (bodipy)[7] and rhodamine,[8] modified to in-
clude ZnII chelating units—that is, dipicolylamine (DPA)—have
previously been described and examined in depth by Nagano
and co-workers.[9] The quinoline-based AQA probe developed
by Zhang et al.[10] is an organic fluorophore and ZnII chelator
that shows excellent ratiometric fluorescence properties upon
zinc binding. Other examples of organic zinc fluorescent
probes have also been developed by Lippard and co-work-
ers.[11]
MRI-based ZnII probes were first developed by Nagano and
co-workers, who attached two DPA units to Gd–DTPA (DTPA=
diethylene triamine pentaacetic acid).[12] This approach to
imaging zinc was also successfully employed by Sherry and co-
workers, who used a probe based around the DOTA motif,
with two DPA ZnII binding units, to image zinc release.[13] Simi-
larly, Pope and co-workers have developed an EuIII 1,4,7,10-tet-
raazacyclododecane-1,4,7-trisacetic acid (DO3A)-based ZnII
sensor,[14] whereas Meade and co-workers have described a ZnII
sensing Gd–DOTA-based (DOTA=1,4,7,10-tetraazacyclodode-
cane-1,4,7,10-tetraacetic acid) chelate that shows a strong zinc-
dependent increase in relaxivity (r1=2.3 mm
1 s1 in the ab-
sence of ZnII and 5.1 mm1 s1 in its presence).[15] Parker and
co-workers have developed DOTA-based ZnII-responsive MRI
contrast agents with GdIII that show a 30–40% increase in r1,
and fluorescent probes with EuIII, which show an increase in
fluorescence intensity upon metal chelation.[16]
The development of dual-modality MR/fluorescent zinc-sens-
ing imaging agents represents a particularly attractive ap-
proach. In principle, this allows the distribution of the probe in
cells and tissues to be explored in vitro with high resolution
and sensitivity prior to in vivo studies using MRI. Thus, Luo
et al. have recently described a DOTA-based chelate attached
to a quinoline derivative that binds ZnII with a relaxivity of
3.8 mm1 s1, a value that increases upon addition of half an
equivalent of ZnII to 5.9 mm1 s1 and decreases back to
5.2 mm1 s1 (at 23 MHz). The fluorescence emission of this
probe also shows a similar increase at up to 0.5 equivalents of
ZnII but decreases in the same manner as the relaxivity.[17]
Nagano et al. also showed that a DTPA–quinoline DPA conju-
gate can be used as a dual MR/fluorescent sensor with GdIII
and a dual fluorescent sensor with EuIII for ZnII, with the latter
showing an increase in fluorescence intensity with ZnII.[18] Pope
and co-workers have shown that a dual fluorescent ZnII sensor
based on DOTA with quinoline and isoquinoline, and which in-
corporates EuIII and YbIII, shows increasing fluorescence upon
ZnII chelation.[19] However, none of these previously described
dual-modal/bimodal probes exhibit ratiometric fluorescence
changes in response to ZnII binding.
Given the high concentration of ZnII ions in insulin gran-
ules,[20] a substantial proportion of which can potentially be un-
bound, and the relative scarcity of zinc ions throughout the
rest of the pancreas,[21] we hypothesised that MRI-active agents
capable of binding ZnII might be useful as a means of quantify-
ing b-cell mass in vivo. Specifically, we used DOTA- and DO3A-
based macrocycles, which are excellent chelating agents for
MRI-active metal ions, and functionalised them to allow both
ZnII binding and the incorporation of fluorescent sensors. Coor-
dination with gadolinium or other MRI-active transition-metal
ions yields novel dual-modal, MR/fluorescent zinc-sensing
probes. We show here that these are tropic for pancreatic b-
cell granules in vitro and indeed we report the first dual-modal
imaging probe to accumulate within granules. Moreover, the
properties (cell permeability and charge) and zinc-dependent
fluorescence of these probes allow them to serve as sensors
for free ZnII within sub-compartments of single cells.
Results and Discussion
Herein we describe dual-modal MR/fluorescent contrast agents
that show specific binding to ZnII as tools to image b-cell mass
and function in diabetes. DO3A is proven to be an excellent
chelate that can be functionalised for many biological imaging
purposes.[22] This macrocycle has been modified with the or-
ganic fluorophore AQA, which has a built-in ZnII sensing motif,
in combination with GdIII to yield a novel dual-modal ZnII sens-
ing probe. Compound Gd·1 shows ratiometric fluorescence
changes with a large Stokes shift from l=410 to 500 nm upon
zinc chelation and Kd=22 mm (pH 7.4). It should be noted that
this wavelength is not ideal for imaging in vivo but is useful
for these proof-of-principle studies. Compound Gd·1 has an
r1=4.2 mm
1 s1 (9.4 T), which increased as high as
6.6 mm1 s1 (9.4 T) upon ZnII binding. When examined in b-cell
lines, Gd·1 (and Eu·1) also showed localisation to secretory
granules identified by co-expression of granule-resident pro-
tein phogrin[23] and relatively poor uptake into non-b cells.
The AQA-DO3A conjugate 6 was synthesised in six steps
from the organic dye 8-aminoquinoline and cyclen. The first
two steps synthesised the AQA dye (2) as described by Zhang
et al.[10] (Scheme 1 and Figure S1 of the Supporting Informa-
tion). The next step conjugated the above organic ZnII sensor
to the cyclen-based chelate DO3A to form the dual-modal or-
ganic framework.[24] Protection of the free amine of the AQA
group with di-tert-butyl dicarbonate is a facile reaction and
gave 3 in 90% yield, thereby preventing the intramolecular
cyclisation of the AQA organic fluorophores under basic condi-
tions. Compound 3 was treated with mesyl chloride to activate
the OH of the protected AQA fluorophore to give 4 in a 90%
yield. The mesyl AQA was treated with tert-butyl DO3A without
side reactions to yield 5 in 77% yield. Compound 6 was
formed by deprotecting the tert-butyl esters with TFA in
a quantitative yield. The DO3A–AQA conjugate can easily com-
plex lanthanide metal ions: GdIII for a ZnII-sensing dual-modal
MR/fluorescent probe, and EuIII for a ZnII-sensing dual-fluores-
cent probe. Compound Gd·1 was synthesised from 6 and
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GdCl3·6H2O in 92% yield; Eu·1 was synthesised from 6 and the
corresponding europium chloride salt in 95% yield.
Compound Gd·1 shows a maximum emission peak at l=
410 nm in the fluorescence spectrum (Figure 1a). This is the
standard emission for the AQA moiety and can be excited at
l=280 and 320 nm.[10] Relaxation measurements at 400 MHz
(9.4 T) on Gd·1 show an r1=4.2 mm
1 s1, which suggests a hy-
dration state (q) of one, much like the ‘gold standard’ MRI con-
trast agent Gd·DOTA, which has an r1=4.2 mm
1 s1.[22, 25] This
is unexpected as the arrangement of the coordinating ligands
suggests that two water molecules should bind. There might
be two possible explanations for this. Either the AQA arm bulk
restricts access of one water from binding to the GdIII metal
centres, as observed by Mishra et al. with a fluorescein isothio-
cyanate (FITC) moiety conjugated to a DO3A motif with an r1
of 5.36 mm1 s1;[26] or the oxygen in the pendant AQA arm
might be bound to the lanthanide metal centre to give an
eight-coordinate structure with one bound water ligand. The q
of 1 was confirmed by the lifetime studies of Eu·1 (Table 1),
and the proton NMR spectrum of Eu·1 (Figure S26 in the Sup-
porting Information) suggests that the oxygen of the AQA side
arm is bound to the lanthanide, thereby causing the q of
1 rather than the steric hindrance from the AQA moiety; this
can be seen by the axial protons around d=25–20 ppm[27] in
the square-antiprismatic (SAP) isomer and d=15–12 ppm in
the twisted square-antiprismatic (TSAP) isomer at room tem-
perature. Figure 1 shows the excitation and emission spectra
for Gd·1 (Figure 1a) and Eu·1 (Figure 1b). There is no difference
in the emission spectrum for the AQA moiety at l=410 nm,
thus indicating that the coordination of the emissive lantha-
nide ion does not change the emission from the AQA moiety.
When excited at l=260 nm, with a zero millisecond delay,
Eu·1 shows both emission from the AQA and EuIII metal at l=
410 and 616 nm, respectively (purple, Figure 1B), thus indicat-
ing that the AQA moiety acts as an organic fluorophore and
an antenna for EuIII. The excitation spectra (blue) when moni-
toring l=410 nm (and l=616 nm, not shown) shows a large
peak at l=250 and 350 nm that corresponds to the AQA
ligand. When the emission and excitation spectra are taken
with a delay of 0.1 ms to eliminate emission from the AQA
given that the lifetimes of organic fluorophores are in the mi-
Scheme 1. Formation of Gd·1. i) Chloroacetyl chloroacetate, pyridine/CHCl3
(79%). ii) 2-(2-Aminoethoxy)ethanol, DIPEA, KI, MeCN (90%). iii) Boc anhy-
dride, pyridine, THF (90%). iv) Methane sulfonyl chloride, DCM, triethylamine
(90%). v) tBu DO3A, K2CO3, DCM, (77%). vi) TFA, DCM (>99%). vii)
GdCl3·6H2O, H2O, pH 5.5 (91%).
Figure 1. A) Fluorescence spectra for Gd·1 showing the excitation spectrum
(dark blue, monitored at l=410 nm) and the emission spectrum (purple, ex-
cited at l=320 nm). B) Luminescence spectra for Eu·1 showing the excita-
tion spectrum with 0 ms delay (dark blue, monitored at l=616, 410 nm), ex-
citation spectrum with 0.1 ms delay (orange, monitored at l=616 nm),
emission spectrum with 0 ms delay (purple, excited at l=350 nm) and emis-
sion spectrum with 0.1 ms delay (light blue, excited at l=350 nm) (pH 7.4,
298 K).
Table 1. Gd·1 versus Zn relaxivity (400 MHz) and Eu·1 versus Zn hydra-
tion state (q) (1 mm Ln·1, pH 7.4, 298 K)
Zn [mm] 0 0.5 1 2 5
Gd·1 r1 [mm
1 s1] 4.2 6.6 5.9 4.6 4.9
Eu·1 q 1.1 1.1 1.1 1.1 1.1
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crosecond range and lanthanide ions are in the millisecond
range, only emission from the EuIII metal (orange and light
blue, respectively; Figure 1B) is observed. The excited state of
amidoquinoline is approximately 20800 cm1,[19] which allows
for energy transfer from the triplet state of the amidoquinoline
to the 5D0 state of the Eu
III metal, that is, approximately
17250 cm1. The form of the spectra for Eu·1 suggests a hydra-
tion state of one (light blue), given that the DJ=1 at 595 nm
is of a relatively similar intensity to that of DJ=2 at 616 nm,
which suggests a coordination geometry of eight rather than
seven, in which case the DJ=1 would be significantly lower
than the DJ=2.[27] This confirms the postulation that the
oxygen on the AQA side arm binds to the metal centre. Com-
pound Eu·1 provides an unusual dual-fluorescent probe, which
has two defined emission wavelengths on two different time-
scales: the millisecond from the lanthanide ion and the nano-
second from the organic fluorophore.
A potential complication of using ZnII as a target for probes
to measure b-cell mass is the presence within the secretory
granules of CaII ions, which might conceivably interfere. Com-
pound Gd·1 shows a ratiometric fluorescent response to ZnII
(Figure 2), such that upon ZnII chelation there is a large
(90 nm) Stokes shift towards the red in emission, from 410 to
500 nm, and a 300% increase in fluorescence amplitude. These
fluorescent properties thus provide the indicator with excellent
ZnII-sensing properties. By contrast, studies with other metals
such as calcium and copper revealed no change in fluores-
cence upon addition of either ion (Figure S2 in the Supporting
Information), thus demonstrating the specificity of Gd·1 as
a fluorescent zinc sensor. The UV/Vis titration of Gd·1 with ZnII
shows an increase in intensity at 250 nm, whereas the UV/Vis
titrations with CaII show binding to Gd·1 (Figure S3 in the Sup-
porting Information), with no formation of this band at
250 nm.
The relaxivity (r1) of Gd·1 is significantly changed when bind-
ing to zinc (Table 1). Thus, in the absence of ZnII, r1 was
4.2 mm1 s1, thus suggesting a hydration state of one. Upon
binding 0.5 equivalents of ZnII, the value of r1 increased to
6.6 mm1 s1. It can therefore be postulated that a metallostar
compound is being created with two Gd·1 units coordinating
one ZnII molecule, as seen previously in similar compounds.[17]
The Eu·1 hydration state remains constant at one, irrespective
of the binding of ZnII. As the concentration of ZnII increases
beyond two equivalents, the relaxivity of Gd·1 drops to r1=
4.9 mm1 s1, still with a hydration state of one, suggesting
a one-to-one ratio of Gd·1 to Zn. The binding of ZnII is postu-
lated therefore to increase second-sphere water ordering, with
possible hydrogen bonding to a solvated zinc to the outer
sphere, thus explaining the increase in r1 from 4.2 to
4.9 mm1 s1.
The dissociation constant of Gd·1 for zinc at pH 7.4 was
measured as 22 mm, a value lower than that of 37 mm for CaII,
thus suggesting that binding of either will be possible in cells
depending on the relative free concentrations of the two. The
selective nature of Gd·1 for ZnII can also be seen in the shift
and increased intensity of the emission, which occurs when
Gd·1 comes into contact with ZnII, but not CaII, thus providing
significant advantages as a sensor for ZnII. This difference in re-
sponses to the two ions can be seen in Figure S4 of the Sup-
porting Information, whereby five equivalents of CaII to Gd·1
elicit no increase in fluorescence emission. Upon addition of
ZnII, in contrast, the emission spectrum increases in intensity
and shifts to 500 nm after the addition of more than 1 equiva-
lent of ZnII. The calculated constant for this interaction match-
es the difference in the constants of Gd·1 to ZnII and CaII. Thus,
Gd·1 shows a ratiometric fluorescent response to ZnII with an
increase in relaxivity, and a Kd potentially in an ideal range for
ZnII sensing in b-cell granules, thereby providing the basis for
an excellent dual-modal imag-
ing agent. It should be noted
that the pH in the granule is ap-
proximately 6,[28] for which the
Kd for Zn
II to Gd·1 was mea-
sured as 111 mm. This has been
confirmed by a pH titration
using Eu·1 (Figure S34 in the
Supporting Information) that
shows a pKa of 7.35, which sug-
gests that amide deprotonation
is vital to ensure tight binding
to ZnII, therefore at pH 7.4 the
affinity is greater than at pH 6
at which a large proportion of
the Ln·1 amide would be pro-
tonated.
Compound Eu·1 shows a ra-
tiometric fluorescent response
to ZnII (Figure 3). Thus, upon ion
chelation, there is a large Stokes
shift towards the red in emis-
sion (by 90 nm from 410 toFigure 2. Gd·1 versus ZnII, fluorescence (1 mm, pH 7.4, 298 K, l=280 nm).
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500 nm), and a 300% increase in fluorescence amplitude from
the organic fluorophore. These values are thus very similar to
those seen in Gd·1 (Figure 2). The inorganic EuIII emission does
not change in intensity, when looking at DJ=4 at 685 nm,
whereas the other EuIII transitions increase in intensity as
a result of being on the tail of the organic AQA ZnII-induced
emission. It must be noted that there is no increase in energy
transfer to the EuIII centre from the AQA chromophore when
bound to ZnII. This is shown by applying a delay of 0.1 ms and
measuring the emission (Figure S5 in the Supporting Informa-
tion) at which there is no change in intensity. To investigate
the mechanism involved in the formation of the emission at
500 nm formed by ZnII chelation, lifetime and quantum yields
of the organic fluorophore were measured (Table S2 and Figur-
es S6–S23 in the Supporting Information). It was found that
the lifetime for Gd·1 at 410 nm was 2.39 ns and with Zn at
410 nm was 2.32 ns. The lifetime when monitoring at 500 nm
increased to 8.82 ns, which is similar to Eu·1. These data corre-
spond to a significant change in the quantum yield, for exam-
ple, 0.0018% for Gd·1 and 0.236% for Gd·1Zn (Table S2 in the
Supporting Information), which suggests speciation when the
zinc is bound. Although these photoluminescent quantum
yields (PLQY) are low, it was also found that excitation at
371 nm of either complex in the presence of ZnII yields emis-
sion of a single non-lanthanide fluorescence band near
500 nm. Absorbance at a 371 nm wavelength is small, though
it is far along the red tail of the absorbance band. Absorption
events at the extreme edges of heavily overlapping absorb-
ance bands might arise in majority owing to a single species
and are evidenced by single-exponential fluorescence decays
that arise owing to selective excitation. Taking together the ex-
citation wavelength dependence of the spectral form of the
emission when ZnII is present and the change to the spectral
form of the excitation spectrum upon addition of ZnII, we sug-
gest that this is indicative of speciation.
This ratiometric response of the AQA unit to zinc, combined
with no response of the EuIII emission, thus provides a dual flu-
orescent probe for determining
ZnII concentration in cells using
the one excitation wavelength
on two different timescales,
that is, the nano- and milli-
second scales. The change in
the lanthanide metal centre in
the DOTA-based chelate gives
the option of a dual-modal zinc
sensor for MR/fluorescence with
GdIII and bimodal fluorescence
with EuIII. To determine whether
Gd·1 is likely to be tropic to-
wards zinc-containing cells in
the pancreas, we first compared
uptake into MIN6 (mouse b-cell-
derived) cells[29] and HEK293
(non-neuroendocrine) cells.
Imaging was performed 30 min
after the addition of Gd·1 (Fig-
ure 4A,D). Consistent with the high ZnII content of b-cell secre-
tory granules,[21] MIN6 cells show a stronger basal signal than
HEK293 cells. Addition of extracellular ZnCl2 significantly in-
creased Gd·1 fluorescence in both MIN6 and HEK293 cells (Fig-
ure 4B, E), with the strongest fluorescence apparent in punctate
structures.
Quantification of this change in fluorescence is shown in Fig-
ure 4C and F. Average fluorescence is charted for three bright
‘spots’ chosen from each cell (red, green and purple from Fig-
ure 4B and E) as well as the average fluorescence of the cell
cluster (black). Fluorescence is not detectably reduced by the
addition of the zinc chelator tetrakis(2-pyridylmethyl)ethylene-
diamine (TPEN), but the addition of zinc and the zinc iono-
phore pyrithione greatly increased fluorescence. Overall, cell
fluorescence was observed to be lower in HEK293 than in
MIN6 cells, which is consistent with the enhancement by gran-
ular zinc of probe fluorescence in the latter. Interestingly, the
low level of fluorescence prior to the addition of zinc/pyri-
thione indicates a free zinc concentration in this compartment
of <1 mm assuming a Kd for zinc of 22 mm, which is in line with
our estimates using protein-based probes.[30]
To ascertain that the bright spots of fluorescence corre-
sponded to the secretory granules, MIN6 and HEK293 cells
were infected with an adenovirus encoding neuropeptide Y-
red fluorescent protein (NPY-RFP).[31] Gd·1 fluorescence was co-
localised with that of NPY-RFP (Figure 4G–L), which is consis-
tent with the accumulation of the zinc probe into secretory
granules in b cells. In contrast, there is negligible co-localisa-
tion in HEK293 cells (Figure 4J–L), which do not possess dense
core secretory granules. The above cellular studies thus show
that Gd·1 is cell-permeable and localises in the granules where
insulin is stored. Cell-toxicity studies were undertaken to show
the biocompatibility of Gd·1. MIN6 and HEK 293 cells were in-
cubated with and without Gd·1 and show 99.4 and 91.9% sur-
vival, respectively. This study (Figures S27–28 in the Supporting
Information), shows that Gd·1 is non-toxic and stable under
biological conditions.
Figure 3. Eu·1 versus ZnII, fluorescence (1 mm, pH 7.4, 298 K, l=280 nm).
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We next explored the MR activity of Gd·1. Phantoms of vary-
ing concentrations were prepared and run at 4.7 T (200 MHz;
Figure S33 in the Supporting Information) with signal intensity
increasing with probe concentration. MRI contrast agents with
AQA moieties have previously been shown to bind human
serum albumin (HSA).[25] Since this interaction is likely to affect
the half-life of Gd·1 in the blood, we determined that this
probe binds HSA as predicted. Figure S33B in the Supporting
Information shows relaxivity of Gd·1 versus [HSA]; the increase
in r1 shows clear binding of Gd·1 to HSA. The observed in-
crease is due to the larger overall mass of the object and
longer tr (rotational correlation time) when Gd·1 binds to HSA.
In vivo this will extend the blood half-life of the contrast
agent. This has also been observed by Lubag and colleagues,
who report on an MR agent that is sensitive to ZnII.[13] This is in
contrast to our approach developed here, which does not rely
on changes in relaxivity dependent upon the secretion of
stored zinc from b cells, but rather on the accumulation of the
probe into cells. As such, our strategy should provide a means
of assessing b-cell mass more than functional b cells. To test
this, human islet cells were incubated for 30 min with Gd·1,
and T1 was measured using a 4.7 T MRI machine. Tubes with-
out cells, which contained only water, gave a T1 of 2806 ms,
tubes with islet cells gave a T1 of 1156 ms and cells incubated
with Gd·1 gave a T1 of 651 ms. This significant reduction in T1
suggests that Gd·1 accumulates inside the islet cells and is re-
tained, thus demonstrating that Gd·1 could be a means to
assess b-cell mass (Figure S29 in the Supporting Information).
To determine whether Gd·1 might also be accumulated into
b cells in vivo, and thus would be useful as a contrast agent
(CA) for b-cell mass, in vivo studies were undertaken. Firstly,
we performed biodistribution studies in which C57/BL6 mice
(n=10) were injected with 200 mg of Gd·1. The organs of the
animals were then harvested at two time points: 30 and
180 min after injection (Figure S30 in the Supporting Informa-
tion). We observed uptake of the agent into the pancreas at
30 min, along with uptake into the kidneys and liver. This bio-
distribution can be attributed to the small size and neutral
charge of the CA. The uptake into the liver presumably reflects
binding to HSA (Figure S33b in the Supporting Information)
and consequent movement to this organ. Of note, by 180 min
these distributions had changed such that there was now
a higher concentration of the agent in the pancreas than in
the liver. This latter phenomenon might be due to the binding
of HSA, thus giving a longer blood half-life, therefore allowing
greater accumulation of the agent in the pancreas and other
organs. Although the uptake in the pancreas increased over
a period of 180 min, the uptake was still low. This is consistent
with the probe being selectively taken up by b cells in the
islet, which account for only 1–2% of the pancreas.
To study further the behaviour of Gd·1 in the living animal,
we next undertook in vivo MRI experiments on healthy C57/
BL6 mice. Mice were injected with CA (Gd·1 or Gd·DOTA) at
0.1 mmolkg1 and scanned over 140 min. This revealed an in-
crease in signal intensity of the pancreas over this period
(Figure 5). The impact on MRI signals of Gd·1 injection was
next compared with that of Gd·DOTA, the ‘gold standard’, but
non-targeted, MRI contrast agent.[22] With Gd·DOTA a large in-
crease in signal intensity over the pancreatic area was ob-
served at 10 min, then a fast decay was seen as the agent was
cleared from blood plasma (Figure 5 and Figure S31 in the
Supporting Information). In contrast, at 140 min there was very
Figure 4. Gd·1 localises to intracellular structures in single cells and displays
Zn2+-dependent changes in fluorescence. Representative images of MIN6
cells stained with A) 50 mm Gd·1, incubated in KREBS buffer and B) after
3 min exposure to KREBS with 0.1 mm ZnCl2 and 5 mm pyrithione. C) Graph
showing the changes in fluorescence of MIN6 cells shown in (A) and (B).
Cells were incubated in KREBS buffer with no further additives (frames 20–
36), KREBS+50 mm TPEN (TPEN), KREBS+5 mm pyrithione+0.1 mm ZnCl2
(ZnPyr) and then KREBS. Black: Whole-cell cluster fluorescence (red, green
and purple): fluorescence of selected granules (shown in B). Representative
images of HEK293 cells stained with D) 50 mm Gd·1 incubated in KREBS
buffer and E) 3 min after the addition of 0.1 mm ZnCl2 and 5 mm pyrithione.
F) Graph showing the changes in fluorescence ratio of HEK293 cells shown
in (D) and (E). Cells were incubated in KREBS buffer with no further additives
(frames 20–36), KREBS+50 mm TPEN (TPEN), KREBS+5 mm pyrithio-
ne+0.1 mm ZnCl2 (ZnPyr) and KREBS again. Black: Whole-cell cluster fluores-
cence (red, green and purple): fluorescence of selected granules (shown in
E). G–L) Representative images of MIN6 and HEK293 cells stained with 50 mm
Gd·1 and infected with an adenovirus encoding NPY-RFP to label dense core
secretory vesicles. MIN6 and HEK293 cells were washed twice with KREBS
buffer, incubated for 5 min with KREBS+0.1 mm ZnCl2 and then imaged.
MIN6 cells show staining with G) Gd·1, H) NPY-RFP, and I) the two signals are
compared with Gd·1 in green and NPY-RFP in red with a magnified selection
inset. HEK293 cells show staining with J) Gd·1, K) NPY-RFP, and L) the two
signals are compared with Gd·1 in green and NPY-RFP in red. Scale bar:
50 mm.
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little increase in signal intensity relative to background. How-
ever, changes in the Gd·1 signal were compatible with a gradu-
al uptake of the agent into the pancreas over 30 min, likely re-
flecting localisation to the b cell and binding to free Zn in se-
cretory granules. This enhancement of the Gd·1 signal relative
to the Gd·DOTA signal continued for approximately 70 min
before both signals gradually declined over a time course of
140 min, ultimately resulting in
an overall 7% increase in signal
intensity relative to the baseline
intensity (Figure 5 and Fig-
ure S32 in the Supporting Infor-
mation).
Conclusion
We describe a dual-modal imag-
ing agent that senses ZnII with
excellent fluorescent and MRI
properties, which might poten-
tially be used to monitor b-cell
mass in vivo. The dual-modal or
dual-fluorescent ZnII probes
Gd·1 and Eu·1 show ratiometric
fluorescence changes with
a large Stokes shift from lem=
410 to 500 nm upon zinc chela-
tion, and a Kd=22 mm (pH 7.4).
Compound Gd·1 has an r1=
4.2 mm1 s1 (9.4 T), which in-
creased up to 6.6 mm1 s1
(9.4 T) upon ZnII binding and
down to 4.9 mm1 s1 with
a large excess amount of ZnII.
Examined in b-cell lines, both
agents also showed localisation
to secretory granules identified
by co-expression of granule-res-
ident protein phogrin, and rela-
tively poor uptake into non-
b cells, thus reflecting excellent
cell permeability, neutral charge
and affinity for ZnII. The Gd·1
probe reveals an intragranular
free ZnII concentration of
1 mm, which is consistent with
our earlier measurements using
non-optimal recombinant pro-
tein-based reporters (estimated
range for intragranular ZnII of
1–100 mm),[30] thus suggesting
that the vast majority of
total ZnII within granules
(30 mm)[20] is complexed to
insulin or other species. Al-
though further validation is re-
quired, our in vivo studies
strongly suggest that Gd·1 is also taken up into the endocrine
pancreas, thus making it a promising imaging agent for assess-
ing b-cell mass. We note that previous studies using zinc chela-
tors in vivo in mammals have demonstrated acceptable safety
profiles.[32] We therefore believe that Gd·1 provides a first-stage
model for the preparation of probes, which might ultimately
be of clinical utility.
Figure 5. A) MRI image of abdomen of a mouse 40 min after injection with Gd·1 (0.1 mmol kg1, pancreas is out-
lined in red). B) MRI image of abdomen of a mouse 40 min after injection with Gd·1 (0.1 mmol kg1, pancreas is
outlined in blue). C) Time-course plot of relative signal intensity change in pancreas after administration of Gd·1
(red) or Gd·DOTA (blue) (0.1 mmol kg1). Structures of Gd·1 (red) or Gd·DOTA (blue) (n=10).
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Experimental Section
General procedures
NMR spectra were recorded using a Bruker Avance DRX 400 spec-
trometer. Chemical shifts are reported in ppm with solvent as inter-
nal reference. Electronic absorption spectra were recorded using
a PerkinElmer UV/Vis spectrometer.
Materials
Solvents and starting materials were obtained from Aldrich, Fluka,
Acros and Alfa. They were used without further purification unless
otherwise stated. Water and H2O refer to high-purity water with
a resistivity value of 18 MWcm1 obtained from the Millipore/MilliQ
purification system. Lanthanide chloride salts were purchased from
Aldrich. The precise metal ion content was determined by colori-
metric titration in acetate buffer (pH 4.5) using a standardised
H2Na2EDTA (EDTA=ethylenediaminetetraacetic acid) solution
(Merck) and Xylenol Orange as indicator.
2-Chloro-N-(quinol-8-yl)acetamide (1)
2-Chloroacetyl chloride (1.3 mL, 16.6 mmol) dissolved in chloroform
(30 mL) was added dropwise to a cooled solution of 8-aminoquino-
line (2.00 g, 13.9 mmol), pyridine (1.6 mL, 19.4 mmol) and chloro-
form (90 mL) over a period of 1 h. After stirring for 2 h at room
temperature, the mixture was concentrated under reduced pres-
sure and the resultant red-brown solid purified by silica gel
column chromatography using dichloromethane to give the prod-
uct as an off-white solid (2.02 g, 79%). 1H NMR (CDCl3): d=10.94
(br, 1H; NH), 8.89 (dd, 3J(H,H)=4.2, 4.2 Hz, 1H; NHCCHCHCH), 8.78
(dd, 3J(H,H)=4.2, 4.2 Hz, 1H; NCHCHCH), 8.21 (dd, 3J(H,H)=8.0,
4.2 Hz, 1H; NHCCHCHCH), 7.59 (m, 2H; NHCCHCHCH, NCHCHCH),
7.51 (q, 3J(H,H)=4.2 Hz, 1H; NCHCHCH), 4.34 ppm (s, 2H; CH2);
13C NMR (CDCl3): d=164.5 (CO), 148.5 (NHCCHCHCH), 136.6
(NCHCHCH), 133.5 (NHCCCCH), 128.0 (NHCCHCHCH), 127.3
(NCHCHCH), 122.6 (NHCCHCHCH), 121.8 (NCHCHCH), 117.0
(NHCCHCHCH), 43.4 ppm (CH2Cl) ; IR: n˜=3325 (NH stretch), 1669
(C=O), 1592 (NH bend), 1328 (CN), 827 cm1 (CCl) ; LC/MS: m/z :
221 [M+H]+ .
2-(2-Aminoethoxy)ethanol-N-(quinol-8-yl)acetamide (2)
Compound 1 (0.24 g, 1.09 mmol), 2-(2-aminoethoxy)ethanol
(1.14 g, 10.9 mmol), N,N-diisopropylethylamine (1.41 g, 10.9 mmol)
and a catalytic amount of potassium iodide (0.14 mmol) were
heated together under reflux conditions in acetonitrile (70 mL).
After 10 h, the mixture was cooled to room temperature and con-
centrated under reduced pressure to give a yellow oil. This was pu-
rified by means of silica gel column chromatography using 20%
MeOH in CHCl3 to give the title compound (0.30 g, 90%).
1H NMR
(CDCl3): d=8.83 (dd,
3J(H,H)=4.1, 1.6 Hz, 1H; NHCCHCHCH), 8.79
(dd, 3J(H,H)=7.1, 1.6 Hz, 1H; NCHCHCH), 8.12 (dd, 3J(H,H)=8.3,
1.4 Hz, 1H; NHCCHCHCH), 7.50 (m, 2H; NHCCHCHCH, NCHCHCH),
7.24 (m, 1H; NCHCHCH), 3.72 (m, 4H; HNCH2CH2O), 3.57 (m, 4H;
OCH2CH2OH), 2.94 ppm (t,
3J(H,H)=4.9 Hz, 2H; CH2NH);
13C NMR
(CDCl3): d=170.8 (CO), 148.5 (NHCCHCHCH), 139.0 (NHCCN), 136.3
(NCHCHCH), 134.2 (NHCCCCH), 128.1 (NHCCHCHCH), 127.3
(NCHCHCH), 121.8 (NHCCHCHCH), 121.5 (NCHCHCH), 116.7
(NHCCHCHCH), 72.3 (COCH2NH), 70.7 (OCH2CH2OH), 61.8
(OCH2CH2OH), 53.8 (NHCH2CH2O), 49.4 ppm (NHCH2CH2O); IR: n˜=
3285 (OH and NH stretch), 1660 (C=O), 1596 (NH bend), 1324 (C
N), 1118 (CO), 1062 cm1 (CO); MS (ESI+): m/z : 290 [M+H]+ .
2,2-(Boc)-aminoethoxy-ethanol-N-(quinol-8-yl)acetamide
(Boc= tert-butyloxycarbonyl) (3)
Compound 2 (590 mg, 2.04 mmol), Boc2O (534 mg, 2.45 mmol) and
Et3N (0.28 mL, 2.04 mmol) were stirred in CH2Cl2 (60 mL) for 12 h.
The reaction was monitored by means of TLC and concentrated
under reduced pressure and purified by means of column chroma-
tography (CH2Cl2–MeOH) as a yellow solid (850 mg, 90%).
1H NMR
(CDCl3): d=10.37 (br, 1H; NH), 8.70 (br, 2H; NHCCHCHCH,
NCHCHCH), 8.20 (d, 3J(H,H)=7.7 Hz, 1H; NHCCHCHCH), 7.57–7.48
(m, 3H; NCHCHCH, NHCCHCHCH, NCHCHCH), 4.23 (m, 2H), 3.77–
3.46 (m, 8H; NCH2CH2O, OCH2CH2OH), 1.45 ppm (s, 9H; (CH3)3) ;
13C NMR (CDCl3): d=169.0 (CO), 155.3 (CO), 148.4 (NHCCHCHCH),
138.5 (NHCCN), 136.3 (NCHCHCH), 134.1 (NHCCCCH), 128.0
(NHCCHCHCH), 127.4 (NCHCHCH), 121.9 (NHCCHCHCH), 121.7
(NCHCHCH), 116.6 (NHCCHCHCH), 81.3 (OC(CH3)3), 72.5 (COCH2NH),
70.3 (OCH2CH2OH), 61.7 (OCH2CH2OH), 54.0 (NHCH2CH2O), 48.5
(NHCH2CH2O), 28.2 ppm ((CH3)3) ; IR: n˜=3326 (OH and NH stretch),
1682 (C=O), 1457 (CH3), 1392 (CH3), 1246 (CO), 1165 (CO),
1136 cm1 (CO); MS (ESI+): m/z : 390 [M+H]+ , 412 [M+Na]+ .
2,2-(Boc)-aminoethoxy-ethyl-methanesulfonate-N-(quinol-8-
yl)acetamide (4)
Compound 3 (395 mg, 1.01 mmol) was dissolved in CH2Cl2 (50 mL)
and cooled to 0 8C. Triethylamine (0.42 mL, 3.04 mmol) and metha-
nesulfonyl chloride (0.20 mL, 2.53 mmol) were then added drop-
wise over 20 min. Following the complete addition of the reagents,
the reaction mixture was stirred for a further 10 min and then at
room temperature for 1 h. The reaction was monitored by means
of TLC, and purified by means of column chromatography (CH2Cl2–
MeOH), 450 mg, 90%. 1H NMR (CDCl3): d=10.36 (br, 1H; NH), 8.70
(br, 2H; NHCCHCHCH, NCHCHCH), 8.20 (d, 3J(H,H)=7.7 Hz, 1H;
NHCCHCHCH), 7.57–7.48 (m, 3H; NCHCHCH, NHCCHCHCH,
NCHCHCH), 4.15–4.27 (m, 4H), 3.76–3.60 (m, 6H), 2.97 (s, 3H;
SO2CH3), 1.45 ppm (s, 9H; (CH3)3) ;
13C NMR (CDCl3): d=168.5 (CO),
155.2 (CO), 148.4 (NHCCHCHCH), 136.3 (NCHCHCH), 134.1
(NHCCCCH), 128.00 (NHCCHCHCH), 127.4 (NCHCHCH), 121.8
(NHCCHCHCH), 116.4 (NHCCHCHCH), 81.3 (OC(CH3)3), 70.4
(OCH2CH2OH), 68.7 (OCH2CH2OH), 54.6 (NHCH2CH2O), 48.6
(NHCH2CH2O), 37.4 (SO2CH3), 28.2 ppm ((CH3)3) ; IR: n˜=3326 (NH
stretch), 1682 (C=O), 1457 (CH3), 1392 (SO2), 1246 (CO), 1165
(CO), 1136 cm1 (CO); MS (ESI+): m/z : 490 [M+H]+ , 468
[M+Na]+ .
tert-Butyl 2,2’,2’’-{[2,2-(Boc)-aminoethoxyethyl-N-(quinol-8-
yl)acetamide]-1,4,7,10- tetraazacyclododecane-1,4,7-triyl} (5)
Compound 4 (71.7 mg, 0.153 mmol) was dissolved in dry acetoni-
trile (15 mL) and added dropwise to a solution of triester cyclen
(94.7 mg, 0.184 mmol) and triethylamine (0.11 mL, 0.767 mmol) in
dry acetonitrile (35 mL). After heating under reflux conditions for
72 h, the resulting reaction mixture was concentrated under re-
duced pressure to give a thick brown oil, which was purified by
means of column chromatography using silica gel (CH2Cl2/CH3OH
95:5) to yield the title compound as a viscous light brown oil
(0.104 g, 77%). 1H NMR (CDCl3): d=10.29 (br, 1H; NCHCHCH), 10.06
(br, 1H; HNCO), 8.78 (m, 2H; NHCCHCHCH,), 8.21 (m, 1H;
NCHCHCH), 7.56–7.50 (m, 2H; NHCCHCHCH, NCHCHCH), 4.13 (2H;
CH2CO), 3.65–3.60 (m, 4H; CH2NCO), 3.45 (br, 2H; CH2O), 4.36–3.46
(16H; 6,8-CH2, 5,9-CH2, 2,12-CH2, 3,11-CH2), 1.42 (s, 9H; CH3),
1.46 ppm (m, 27H; CH3) ;
13C NMR (CDCl3): d=172.6 (CO), 170.5
(CO), 169.7 (CO), 168.1 (CO), 148.4 (NHCCHCHCH), 138.3 (NHCCN),
136.5 (NCHCHCH), 128.0 (NHCCHCHCH), 127.3 (NCHCHCH), 121.9
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(NHCCHCHCH), 116.3 (NHCCHCHCH), 82.3 (OC(CH3)3), 81.8
(C((CH3)3)2), 81.6 (C(CH3)3), 76.1 (COCH2NH), 70.0 (OCH2CH2OH), 58.2
(CO(CH3)3), 56.5 (OCH2CH2OH), 55.7 (NHCH2CH2O), 52.7
(NHCH2CH2O), 51.3 (CO(CH3)3), 50.3 (6,8-CH2), 49.2 (5,9-CH2), 48.4
(2,12-CH2), 47.5 (3,11-CH2), 28.2 (CH3), 28.0 (CH3)2, 27.9 ppm ((CH3)3) ;
ESI-MS: m/z : 887 [M+H]+ , 909 [M+Na]+ .
2,2’,2’’-{[2-Aminoethoxyethyl-N-(quinol-8-yl)acetamide]-
1,4,7,10-tetraazacyclododecane-1,4,7- triacetic acid} (6)
Compound 5 (50 mg, 0.0564 mmol) was dissolved in dichlorome-
thane (3 mL) and trifluoroacetic acid (3 mL) was added dropwise.
After stirring overnight at room temperature, the volatile com-
pounds were removed under a stream of N2. The oily residue was
dissolved in water and washed with dichloromethane. The aque-
ous layer was reduced under vacuum to leave a light yellow oil.
1H NMR (D2O): d=8.95 (d,
3J(H,H)=5.9 Hz, 1H; NCHCHCH), 8.63 (d,
3J(H,H)=7.3 Hz, 1H; NHCCHCHCH), 8.41 (d, 3J(H,H)=9.8 Hz, 1H),
7.77 (d, 3J(H,H)=7.6 Hz, 1H; NCHCHCH), 7.63 (m, 2H; NHCCHCHCH,
NCHCHCH), 4.36–3.46 ppm (32H; CH2CO, CH2NCO, 6,8-CH2, 5,9-
CH2, 2,12-CH2, 3,11-CH2, HNCH2CH2O, OCH2CH2N);
13C NMR (D2O):
d=174.1 (CO), 167.2 (CO), 162.8 (CO), 148.4 (NHCCHCHCH), 144.8
(NCHCHCH), 133.6 (NHCCN), 133.1 (NHCCHCHCH), 130.0
(NCHCHCH), 129.9 (NHCCHCHCH), 129.2 (CHN), 125.9 (CCCH) 122.2,
(NHCCHCHCH), 65.9 (NH COCH2), 65.7 (OCH2CH2NH), 54.5 (CO), 53.5
(OCH2CH2N), 52.9 (NCH2CO), 51.6 (NCH2CO), 48.3 (NCH2CO), 47.9
(ring-CH2), 47.1 ppm (ring-CH2); MS (ESI+): m/z : 618 [M+H]
+ .
Gd·2,2’,2’’-{[2-aminoethoxy-ethyl-N-(quinol-8-yl)acetamide]-
1,4,7,10-tetraazacyclododecane- 1,4,7-triacetate} (Gd·1)
Compound 6 (0.031 g, 0.050 mmol) was dissolved in H2O (5 mL) at
room temperature. Following the addition of GdCl3·6H2O (0.018 g,
0.050 mmol), the pH of the solution was adjusted to 5.5 by NaOH
(1m). After 5 h, the pH was further adjusted to 10.8 and left for
40 min. The white precipitate was centrifuged and the supernatant
separated and concentrated under reduced pressure to exactly
1 mL. The complex was purified using a Sephadex G-25 size exclu-
sion column, eluting with water. The aliquots that contained the
complex were combined and the desired complex was obtained as
a hygroscopic solid (0.039 g 91%). MS (ESI+): m/z : 773 [M+H]+ ;
MS (ESI+): m/z calcd for C29H41GdN7O8: 773.2179; found: 773.2241.
Eu·2,2’,2’’-{[2-aminoethoxy-ethyl-N-(quinol-8-yl)acetamide)]-
1,4,7,10-tetraazacyclododecane-1,4,7-triacetate} (Eu·1)
Compound 6 (0.031 g, 0.050 mmol) was dissolved in H2O (5 mL) at
room temperature. Following the addition of EuCl3·6H2O (0.017 g,
0.050 mmol), the pH of the solution was adjusted to 5.5 by NaOH
(1m). After 5 h, the pH was further adjusted to 10.8 and left for
40 min. The white precipitate was centrifuged and the supernatant
separated and concentrated under reduced pressure to exactly
1 mL, then the complex was purified using a Sephadex G-25 size
exclusion column and eluting with water. The aliquots that con-
tained the complex were combined and the desired complexes
were obtained as a hygroscopic solid (0.038 g 90%). 1H NMR
(400 MHz, D2O, 278 K): d=26.45, 21.84, 21.48, 18.59, 17.21, 16.01,
15.08, 13.38, 12.76, 12.06, 8.78, 8.25, 7.95, 7.83, 7.10, 6.26, 6.18,
3.45, 2.83, 1.90, 0.64, 0.35, 0.39, 1.65, 2.65, 3.17, 4.22,
4.47, 6.24, 7.74, 7.96, 9.07, 9.30, 10.44, 11.19, 13.55,
15.43, 16.29, 18.80, 20.24, 22.36 ppm; MS (MALDI-TOF):
m/z : 768 [M+H]+ .
Relaxivity measurements
Compound Gd·1 was prepared in situ by mixing the appropriate
amounts of ligand and GdCl3·6H2O (99.99%; Aldrich) in H2O fol-
lowed by adjustment of the pH with NaOH aqueous solution
(pH 7.4) for relaxivity measurements. The resulting solution was
placed in a 1.7 mm diameter capillary, which was sealed. The ab-
sence of free gadolinium was checked in all samples by the xylenol
orange test. The 1/T1 measurements were performed using
a Bruker DRX 400 spectrometer (400 MHz).
Luminescence spectroscopy
Luminescence measurements (spectra and lifetimes) were recorded
using a Cary Varian eclipse luminescence spectrometer. The excita-
tion source was a 450 W Xe arc lamp and all spectra were correct-
ed for detection and optical spectral response (instrumental func-
tions) of the spectrofluorimeter. Phosphorescence lifetimes were
measured in the time-resolved mode. They are averages of three
independent measurements that were taken by monitoring the
decay at the maxima of the emission spectra. The monoexponen-
tial decays were analysed by using Graph Pad Prism 5. Samples
were held in a 1010 nm or 104 nm quartz Hellma cuvette and
cutoff filters were used to avoid second-order diffraction effects.
Metal-binding titrations
Relaxivity : Compound Gd·1 was prepared as above at 1 mm con-
centration to which ZnCl2 in H2O was added to give the appropri-
ate concentration of Zn to Gd·1. The 1/T1 was measured as above.
Fluorescence and UV/Vis spectroscopy : Compound Gd·1/Eu·1
was prepared at 0.1 mm concentration to which ZnCl2 or CaCl2 in
10 mmol HEPES buffer at pH 7.4 were added to give the appropri-
ate concentration of Zn to Gd·1/Eu·1. The data were fitted on
Graph Pad Prism and using an iterative least-square fitting proce-
dure operating in Microsoft Excel.
Fluorescence lifetimes : Recorded using time-correlated single-
photon counting (TCSPC) in 10 mm quartz cuvettes. Excitation
sources were a Horiba JY NanoLED pulsed diode laser with 1 MHz
repetition rate at nominal wavelength of 371 nm, or a Coherent
Verdi-pumped, frequency-trebled MIRA-900 Titanium-Sapphire
laser with a pulse-switch radiofrequency cavity dumper and nomi-
nal wavelength of 296 nm. Fluorescence was detected orthogonal-
ly to the excitation path and determined using a Jobin Yvon Triax
190 monochromator. The instrument response was recorded at the
excitation wavelength with Ludox colloidal silica as the scattering
medium in a 10 mm quartz cuvette. Fluorescence was recorded
with a minimum of 10000 counts at the peak of the pulse height
analyser and the data were fitted by iterative reconvolution of
a sum of exponential functions with the instrument response. The
reduced c2 parameter quantifies the goodness-of-fit, the Durbin–
Watson parameter quantifies the autocorrelation, and the random-
ness of residuals and auto-correlated residuals permit a secondary
analysis of both the goodness-of-fit and the true state of the auto-
correlation function.
Fluorescence quantum yields : Measured using the relative
method over at least four different concentrations described in
detail elsewhere.[33] For the analyte emission near 410 nm, the stan-
dard was quinine sulphate in aqueous 0.1m sulphuric acid (fr=
0.55), and for the emission at 500 nm, the standard was fluorescein
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in aqueous 0.1m sodium hydroxide (fr=0.89). Solutions of LnM
were prepared in 10 mm HEPES buffer, with 1 equivalent of zinc
sulfate. Absorbance was measured at 312 nm to avoid absorbance
by the buffer and all solutions were excited at this wavelength for
emission spectra. Emission spectra were fully corrected for instru-
ment response and background fluorescence and integrated be-
tween constant limits. Emission near 410 nm was integrated be-
tween 360 and 420 nm, and emission near 500 nm was integrated
between 500 and 550 nm. All integrated bands had an uncorrected
detector response within the linear range of the detector. Linear
least-squares regression of integrated emissions versus 1–10A
gave R2 goodness-of-fit parameters of greater than 0.99. The quan-
tum yields were calculated according to Equation (1) below:
f ¼ r
mf
mr
 
h2f
h2r
ð1Þ
in which ff,r are the quantum yields (f= sample, r= reference), mf,r
are the gradients of integrated emission versus 1–10-A and hf,r are
their refractive indices (hf,r=1.33).
pH titrations : A 1 mm solution of Eu·1 in 0.1m KCl (3 mL) was pre-
pared. The pH of the solution was monitored and adjusted to
acidic or basic conditions using aliquots of 1m HCl or 1m NaOH
solution, respectively. The pH was allowed to stabilise. The fluorim-
eter was operated using an excitation slit width of 20 nm and an
emission slit width of 5 nm. An excitation wavelength of 325 nm
was used. The same was also carried out with Eu·1 and 1 equiva-
lent of Zn.
In vitro cell growth and imaging
HEK293 cells were cultured in Dulbecco’s modified eagle’s medium
(DMEM; Lonza) supplemented with 10% fetal bovine serum (FBS;
Lonza), 1% glutamine (Lonza) and 1% penicillin/streptomycin
(Gibco). MIN6 cells were cultured in DMEM supplemented with
15% FBS, 1% glutamine, 1% penicillin/streptomycin, 50 mm b-mer-
captoethanol (Fluka) and 10 mm 4-(2-hydroxyethyl)-1-piperazine-
ethanesulfonic acid (HEPES). Two days prior to imaging, cells were
grown in coverslips in six-well flat-bottomed plates. For NPY-RFP
studies, cells were infected with 1.5105 pfu of an adenovirus en-
coding NPY-RFP the day before visualisation.[31]
On the day of visualisation, cells were washed twice with KREBS
buffer (140 mm NaCl, 3.6 mm KCl, 0.5 mm NaH2PO4, 0.2 mm MgSO4,
1.5 mm CaCl2, 10 mm HEPES (pH 7.4), 2 mm NaHCO3) pre-equilibrat-
ed with 95:5 O2/CO2 that contained 25 mm glucose. They were
then incubated with KREBS+50 mm Gd·1 for 30 min and washed
twice with KREBS buffer. Cells were visualised every 5 s for 10 min.
After 3 min (36 images), 50 mm N’,N’,N’-tetrakis(2-pyridylmethyl)-
ethylenediamine (TPEN) was added. After 6 min (72 images), TPEN
was removed and 0.1 mm ZnCl2 and 5 mm pyrithione were added.
After 9 min (108 images), ZnCl2 and pyrithione were removed.
Images were captured using an Olympus IX-70 wide-field micro-
scope with a 40 oil immersion objective and an Imago charge-
coupled device camera (Till Photonics, Grafelfing, Germany) con-
trolled by TILLvisION software (Till Photonics) or with an sCMOS
camera (Zyla, Andor) controlled by micromanager.[34] For all
images, microscope settings such as brightness, contrast and expo-
sure time were held constant to compare the relative intensity of
Gd·1 and NPY-RFP.
For viability assays, HEK293 and MIN6 cells were grown overnight
as above. Ninety minutes prior to visualisation, cells were either in-
cubated in KREBS buffer or KREBS buffer that contained 50 mm
Gd·1 and grown for an hour. Thirty minutes before visualisation,
propidium iodide (3 mL) and 1.5 mm Calcein-AM were added to
each 2 mL well. Cells were visualised using a Zeiss Axiovert confo-
cal microscope coupled to a Nipkow spinning-disk head (Yokoga-
wa CSU-10) using a 40 air objective. A solid-state laser (CrystaLas-
er) controlled using a laser-merge module (Spectral Applied Phys-
ics) provided wavelengths of 491 nm to excite propidium iodide,
and wavelengths of 561 nm to excite Calcein-AM. Images were
captured using a highly sensitive 16-bit, 512512 pixel back-illumi-
nated EM-CCD camera (ImageEM 9100-13; Hamamatsu). Volocity
software (PerkinElmer) provided the user interface.
After initial acquisition Triton X-100 (0.2%) was added to each well
and 10 min later cells were visualised to check for effective PI stain-
ing and removal of Calcein-AM staining. For all images, microscope
settings such as brightness, contrast and exposure time were held
constant.
Magnetic resonance imaging
Compound Gd·1 (1 mL) in Eppendorf tubes at concentrations of
0.05, 0.3, 0.75, 0.1, 0.25, 0.5 and 1 mm were placed in a 4.7 T MRI
scanner. A T1 inversion recovery experiment was undertaken to
provide the images seen in Figure S31 of the Supporting Informa-
tion.
Human serum albumin (HSA) at increasing concentrations was
added to Gd·1 (1 mL, 0.1 mm) and were placed in a 4.7 T scanner
and a T1 inversion recovery experiment was undertaken to give the
data seen in Figure S31 of the Supporting Information.
Human islets (Diabetes Research Institute OSR-DRI, San Raffaele
Scientific Institute) were isolated post mortem from heart-beating
donors with suitable ethical permissions and used with local ethi-
cal committee approval (NRES Committee London, Fulham 07/
H0711/114). Islets were incubated in either 2 mL islet media (RPMI
supplemented with 10% FBS and 1% penicillin/streptomycin), or
2 mL islet media that contained X = 1mm Gd·1 for 2 h. The islets
were washed twice with 1 mL islet media, transferred to a 50 mL
tube, and any remaining media were removed. The islet pellet was
sealed in place by covering with 4% low-melting point agarose in
PBS (50 mL). A second control consisted of 4% low-melting point
agarose in PBS (100 mL).
In vivo studies
In vivo experiments were conducted in coherence to Swiss animal
welfare legislation. The experiment was covered by the animal li-
cense BS-1418. The study was conducted with Balb/C mice of
19 months of age (BW approx. 20–24 g) (n=10 animals).
Anaesthesia : Isoflurane 1–3 vol% in O2 induced outside the
magnet in an anaesthesia box. A tail vein catheter was placed
under anaesthesia outside of the magnet and the animal immedi-
ately thereafter was placed on a cradle in the magnet. The animal/
pancreas was fixed with tape to reduce respiration movement.
Localisation of pancreas with TriPilot and TriPilot-multi pro-
tocols
TriPilot (12 s 800 ms): Gradient echo sequence with TE: 3 ms, TR:
100 ms, FoV: 6060 mm, slice thickness: 2.00 mm, slices: 1, matrix
size: 256256.
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TriPilot-multi (25 s 600 ms): Gradient echo sequence with TE:
3 ms, TR: 200 ms, FoV: 6060 mm, slice thickness: 1.00 mm, three
orthogonal sections with slices: five each, matrix size: 256256.
Two baseline acquisitions with T1wMSME followed by Gd·1 or
DOTAREM infusion and a series of 14 consecutive T1wMSME ac-
quisitions every 10 min for 2 h 20 min were performed.
T1wMSME (8 min 57 s 600 ms): Spin-echo sequence with TE:
14.2 ms, TR: 350 ms, FoV: 5050 mm, slice thickness: 0.6 mm,
slices centred on the pancreas: 16, matrix size: 256192, NA=8.
Slow in vivo infusion of Gd·1 at 0.1 mmolkg1 or DOTAREM at
0.1 mmolkg1 was performed in the tail vein by a remote infusion
pump with the animal positioned in the magnet.
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